Yan Zhang

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Chunmeng Wang, Zhiqiang Wu, Yao Wang et al. · Clinical Cancer Research · 2016 · 323 citations

CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

Jing Pan, Qing Niu, Biping Deng et al. · Leukemia · 2019 · 242 citations · Full text

Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Yao Wang, Wenying Zhang, Qingwang Han et al. · Clinical Immunology · 2014 · 190 citations

Lymphoid Neoplasia, Delayed Toxicities, Effective Response +8

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

Hanren Dai, Wenying Zhang, Xiaolei Li et al. · OncoImmunology · 2015 · 164 citations · Full text

Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Wenying Zhang, Yao Wang, Yelei Guo et al. · Signal Transduction and Targeted Therapy · 2016 · 130 citations · Full text